Medscape13h
Bladder Cancer Survival Better with Nivolumab than Placebo in New Analysis
Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
Hosted on MSN21h
No OS Boost With Palbociclib and Endocrine Therapy in Premenopausal Breast Cancer
No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
This was the stock's third consecutive day of gains.
Gilead’s lenacapavir under priority review could revolutionise HIV PrEP
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
Gilead price target raised to $120 from $105 at Bernstein
Bernstein raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes Gilead ...
Gilead’s Seladelpar granted conditional European marketing authorization
Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...
Healthcare sector takes the lead in 2025 as market volatility rises
The Healthcare sector of the economy is front and center on Friday as shares of UnitedHealth drop 7.8%, spurring a widespread market selloff across the broader market a ...
Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...